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Type 1 fimbriae are surface-located adhesion organelles of Escherichia coli that are directly associated with
virulence of the urinary tract. They mediate D-mannose-sensitive binding to different host surfaces by way of
the minor fimbrial component FimH. Naturally occurring variants of FimH that bind strongly to terminally
exposed monomannose residues have been associated with a pathogenicity-adaptive phenotype that enhances
E. coli colonization of extraintestinal locations such as the urinary tract. The FimH adhesin also promotes
biofilm formation in a mannose-inhibitable manner on abiotic surfaces under static growth conditions. In this
study, we used random mutagenesis combined with a novel selection-enrichment technique to specifically iden-
tify mutations in the FimH adhesin that confer on E. coli the ability to form biofilms under hydrodynamic flow
(HDF) conditions. We identified three FimH variants from our mutant library that could mediate an HDF bio-
film formation phenotype to various degrees. This phenotype was induced by the cumulative effect of multiple
changes throughout the receptor-binding region of the protein. Two of the HDF biofilm-forming FimH variants
were insensitive to mannose inhibition and represent novel phenotypes not previously identified in naturally
occurring isolates. Characterization of our enriched clones revealed some similarities to amino acid alterations
that occur in urinary tract infection (UTI) strains. Subsequent screening of a selection of UTI FimH variants
demonstrated that they too could promote biofilm formation on abiotic surfaces under HDF conditions. In-
terestingly, the same correlation was not observed for commensal FimH variants. FimH is a multifaceted pro-
tein prone to rapid microevolution. In addition to its previously documented roles in adherence and invasion,
we have now demonstrated its function in biofilm formation on abiotic surfaces subjected to HDF conditions.
The study indicates that UTI FimH variants possess adaptations that enhance biofilm formation and suggests
a novel role for FimH in UTIs associated with medical implants such as catheters.
Most bacteria living in aquatic environments form sessile
communities referred to as biofilms. Biofilms are compact mi-
crobial communities consisting of organisms adherent to each
other and/or a target surface. They can consist of either
monocultures or multispecies communities and show extra-
ordinary resistance to mechanisms that efficiently remove free-
swimming bacterial relatives (8, 9). Bacterial biofilms can es-
tablish on virtually any solid surface of inorganic or organic
nature spanning a wide spectrum of environments (8). Bacte-
rial adherence is instrumental for the successful establishment
of sessile bacterial communities on mammalian tissue surfaces,
notably on surfaces subjected to hydrodynamic flow (HDF)
shear forces such as the urinary tract. The best-characterized
group of bacterial adhesins is constituted by fimbriae (13).
Type 1, or mannose-sensitive, fimbriae are found on the ma-
jority of Escherichia coli strains and are widespread among
other members of the family Enterobacteriaceae (16). Interac-
tion between type 1 fimbriae and receptor structures has in a
number of studies been shown to play a key role in the colo-
nization of various host tissues by E. coli (2, 40). Also, in cer-
tain strain backgrounds type 1 fimbriae can be regarded as
virulence factors. Indeed, we and others have previously shown
that the expression of type 1 fimbriae in E. coli is linked to
urinary tract colonization and pathogenesis (7, 25, 36). In an-
imal models, immunization with the type 1 fimbrial adhesin
was shown to prevent urogenital mucosal infection by E. coli
(20, 21).
A typical type 1-fimbriated bacterium has 200 to 500 peri-
trichously arranged fimbriae on its surface. A type 1 fimbria is
a 7-nm-wide, approximately 1-mm-long, rod-shaped structure
consisting of four different components that are added to the
base of the growing organelle (22). The bulk of the structure
consists of about 1,000 copies of the major subunit protein,
FimA, polymerized into a right-handed helical structure, but
small quantities of the minor components, FimF, FimG, and
FimH are also present (14, 19). It has been shown that the
receptor-recognizing element of type 1 fimbriae is the 30-kDa
FimH protein (18). FimH is located at the organelle tip in a
short fibrillum and perhaps additionally intercalated along the
fimbrial shaft (12, 18). The FimF and FimG components seem
to be required for integration of the FimH adhesin into the
fimbriae (12, 14). The components of the fimbrial organelle are
encoded by the chromosomally located fim gene cluster (15).
In addition to the structural components, this 9.5-kb DNA
segment also encodes the fimbrial biosynthesis machinery as
well as regulatory elements (Fig. 1).
By virtue of the FimH adhesin, type 1 fimbriae mediate
adhesion to a variety of mannosylated glycoproteins. Addition-
ally, a number of studies have revealed that FimH adhesins
from certain clinical isolates confer binding to protein targets
such as fibronectin and collagen. This specificity change was
found to be due to minor variations in the amino acid sequence
of FimH (27, 38). Also, the affinity of FimH variants toward
mannose targets can vary due to changes in the primary struc-
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ture. In about 80% of fecal E. coli isolates, the FimH adhesin
is capable of binding only to trimannose receptors. In contrast,
the FimH adhesins from approximately 70% of urinary tract
isolates carry minor mutations (compared to the fecal isolates)
that enhance their ability to recognize monomannose recep-
tors (37). The mutant alleles confer a significantly higher tro-
pism for the uroepithelium (36).
The FimH adhesin has been shown to be instrumental in
biofilm formation by E. coli K-12 under static growth condi-
tions (28). Type 1 fimbriae were found to be critical for the
initial interaction of E. coli cells with abiotic surfaces. Further-
more, this attachment could be inhibited by D-mannosides,
indicating a specific role for FimH in such interactions. The
FimH adhesin is a two-domain protein, with the NH2-terminal
half conferring its lectin-binding characteristics (5, 17, 21, 33,
39). In a previous study we described the construction of a
FimH mutant library by PCR-induced random mutagenesis
within this region of the fimH gene (34). Specific mutations
that altered the ability of FimH to bind to monomannose,
oligomannose, and protein targets were identified. In this work
we have screened the same FimH mutant library for variants
with an ability to confer biofilm formation under HDF condi-
tions, i.e., a scenario that arguably mimics many natural envi-
ronments better than static conditions.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The strains and plasmids
used in this study are listed in Table 1. E. coli K-12 strain HB101 (F9 lacIq kan)
(3) was used as an intermediate host during plasmid construction work. All
subsequent phenotypic analyses were performed in the E. coli Dfim strain S1918
(4). The FimH expression vector pMAS1 contains the fimH gene from E. coli
K-12 strain PC31 (15) under transcriptional control of the lac promoter. In
addition, the plasmid contains unique KpnI and HincII recognition sequences
within the fimH gene that flank the region encoding the proposed FimH recep-
tor-binding domain (Fig. 1). Cells were grown in Luria-Bertani (LB) broth (30)
supplemented with the appropriate antibiotics.
DNA techniques. Plasmid DNA was isolated using a QIAprep spin plasmid kit
(Qiagen). Restriction endonucleases were used as specified by the manufacturer
(New England Biolabs or Pharmacia). The nucleotide sequences were deter-
mined on both DNA strands by the dideoxynucleotide chain termination method
(31). Oligonucleotide primers were purchased from Gibco BRL.
Construction of the fimH mutant library. Construction of the fimH mutant
library has been described previously (34). Briefly, the 650-bp KpnI-HincII frag-
ment of the fimH gene from pMAS1 was mutagenized by nucleotide misincor-
poration during suboptimal PCR conditions. Four reactions were performed,
with three of the four nucleotides at a concentration of 50 mM and the other at
5 mM. Each reaction mixture also contained 7 mM MgCl2 to increase the
stability of noncomplementary base pairs and 0.5 mM MnCl2 to reduce the
template specificity of the polymerase. The error-prone PCR procedure was
performed for 35 cycles with two primers that flank the KpnI and HindII sites of
the fimH gene. The amplification products were combined, digested with KpnI
and HincII, purified after agarose gel electrophoresis, and religated into similarly
cut plasmid pMAS1 to construct a library of altered fimH genes. To permit
expression of the corresponding FimH variants as functional constituents of type
1 fimbriae, the ligation mix was transformed into E. coli strain S1918 (Dfim)
containing an auxiliary plasmid, pPKL115, which encodes the entire fim gene
cluster except fimH. The transformation mixture was made up to 10 ml, grown to
approximately 10 times the initial library diversity, and stored as aliquots at
280°C in 25% (vol/vol) glycerol. Analysis of 300 random transformants revealed
that the mutagenesis procedure was highly successful, with approximately 60% of
transformants displaying an altered yeast agglutination phenotype.
Construction of defined fimH mutations. Specific amino acid substitutions
from the mutant fimH genes were introduced into the wild-type fimH sequence
by overlapping PCR. The following primers were used: ms1 (59-GTGATAAGC
TTCACCATACCTACAGC), ms2 (59-GCTCGAATTCCAGCATTAGCAATG
TCC), 137 (59-ATAATCGAGAACGGATAAGC), and 138 (59-GCTTATCCG
TTCTCGAATTAT). Each construct was sequenced to ensure fidelity of the
FIG. 1. Schematic representation of plasmids used to display FimH variants. Plasmid pPKL115 contains the entire fim gene cluster with a
translational stop linker inserted into the fimH gene (triangle). Plasmid pMAS1 is the fimH expression vector upon which all functional variants
constructed in this study are based. The segment flanked by the KpnI and HincII sites was submitted to mutagenesis. Only relevant nonvector
regions are shown.
TABLE 1. Strains and plasmids used in this study
Strain or
plasmid Relevant genotype
Refer-
ence
E. coli strains
HB101 F9 laqIq 3
KB28 fimH gene from wild-type strain CI#10 37
KB53 fimH gene from wild-type strain CI#4 37
KB91 fimH gene from commensal strain F-18 37
KB96 fimH gene from wild-type strain MJ2-2 37
S1918 F9 laqIq DfimB-H::kan 4
MS72 pMAS1 and pPKL115 in S1918 This study
MS174 pMAS58 and pPKL115 in S1918 This study
MS202 pMAS60 and pPKL115 in S1918 This study
MS206 pMAS64 and pPKL115 in S1918 This study
PK799 pPKL236 and pPKL115 in S1918 This study
PK800 pPKL238 and pPKL115 in S1918 This study
PK802 pPKL237 and pPKL115 in S1918 This study
PK803 pPKL239 and pPKL115 in S1918 This study
TK130 pTBK31 and pPKL115 in S1918 This study
Plasmids
pPKL4 Wild-type fim gene cluster 15
pPKL115 All fim genes except fimH 26
pMAS1 fimH gene in pUC19 32
pMAS58 Modified fimH gene (V28A, V56A, F71L,
Y82H, T87A, V94A, W103R, S113G,
V118A)
This study
pMAS60 Modified fimH gene (V30L, G73E, S114R,
N136Y, Q143L, V155G)
This study
pMAS64 Modified fimH gene (G73E, L107F) This study
pPKL236 Modified fimH gene (W103R, S113G, V118A) This study
pPKL237 Modified fimH gene (V28A, V56A, F71L,
Y82H, T87A V94A)
This study
pPKL238 Modified fimH gene (S114R, N136Y, Q143L,
V155G)
This study
pPKL239 Modified fimH gene (V30L, G73E) This study
pTBK31 Modified fimH gene (G73E) This study
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PCR. Plasmids containing these chimeric fimH genes were introduced into
S1918(pPKL115) and tested for yeast agglutination and biofilm formation.
Biofilm screening assay. An aliquot of the fimH mutant library was grown
overnight in LB and diluted to approximately 108 cells ml21 in phosphate-
buffered saline (PBS), and 100-ml aliquots were placed in 10 wells of a polysty-
rene microtiter plate. The plate was incubated at 37°C for 1 h with shaking and
washed with 10 times with PBS; any remaining bound cells were then resus-
pended in 100 ml of LB. Following growth overnight at 37°C with shaking the
cells were diluted to approximately 108 cells ml21, and the procedure was carried
out three more times. After the last incubation, the cultures were streaked for
single colonies.
Assays for biofilm formation under hydrodynamic growth conditions were
performed as previously described (10), with some modifications. Briefly, early-
exponential-phase cultures (optical density at 600 nm [OD600] 5 0.2) were
incubated in 100-ml volumes in a microtiter plate well for 16 h with vigorous
shaking. Unbound cells were removed by inversion of the microtiter plate and
tapping on absorbent paper. Adhered cells were subsequently stained by the addi-
tion of 200 ml of 0.1% crystal violet. The stain was removed by thorough washing
with PBS, and the wells were allowed to dry. The crystal violet was solubilized by the
addition of 200 ml of ethanol-acetone (80:20, wt/wt), and A600 was determined.
Agglutination of yeast cells. The capacity of bacteria to express a D-mannose-
binding phenotype was assayed by their ability to agglutinate yeast (Saccharo-
myces cerevisiae) cells on glass slides. Aliquots of washed bacterial suspensions at
OD550 5 0.5 and 5% yeast cells were mixed, and the time agglutination occurred
was measured. Furthermore, clones which did not cause any agglutination under
these conditions were also tested at OD550 5 20 and/or low temperature but still
did not react.
RESULTS
Identification of FimH variants capable of HDF biofilm
formation. In E. coli K-12, type 1 fimbriation was shown to be
critical for biofilm formation on abiotic surfaces under static
growth conditions; this property could be abolished by addition
of methyl-a-D-mannopyranoside, indicative of FimH involve-
ment (Fig. 2A) (28). However, under HDF conditions, the
wild-type (wt) FimH adhesin was unable to confer biofilm
formation (Fig. 2B). We hypothesized that variants of the
FimH adhesin that would induce biofilm formation under
HDF conditions could be selected for. To identify such vari-
ants we screened our FimH mutant library, which consists of a
pool of fimH genes with PCR-introduced random mutations
within the receptor-binding region of the FimH adhesin. More
specifically, the mutagenesis was targeted to the region encom-
passing amino acids 8 to 225 of the mature FimH protein (34).
An aliquot of the FimH mutant library (approximately 108 cells
ml21) was incubated in a polystyrene microtiter plate and
subjected to the selection-enrichment procedure described in
Materials and Methods.
Fifty colonies enriched by this procedure were randomly
selected and tested for biofilm formation under HDF condi-
tions on a polystyrene surface. This involved growth of each
clone in a microtiter plate for 16 h with vigorous shaking,
removal of unbound cells, and subsequent staining of bound
cells with 0.1% crystal violet. Cells attached to the abiotic
surface could be visualized, as they were stained purple with
crystal violet. Thirty (60%) of the fifty colonies were observed
to form a biofilm under these conditions. To ensure that the
observed biofilm-forming phenotype was indeed the result of
specific alteration of the fimH gene, each of the 30 fimH-
encoding plasmids was purified and retransformed into S1918
FIG. 2. Biofilm formation by E. coli cells expressing FimH variants. Each FimH variant is indicated by its expression plasmid. (A) Biofilm
formation on a microtiter plate surface by cells expressing the K-12 fimH allele when grown in LB under static conditions. (B) Biofilm formation
on a microtiter plate surface by cells expressing FimH variants when grown in LB under HDF conditions. Note that no biofilm is produced by the
K-12 fimH allele (pMAS1) under these conditions. (C) Quantification of biofilm formation as determined by the amount of crystal violet staining
for each of the FimH variants. All experiments were performed in the presence and absence of methyl-a-D-mannopyranoside (a mm). Results are
expressed as the average of four independent experiments (6 standard deviation).
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(pPKL115). The new recombinant clones displayed the same
biofilm-forming phenotype as the original isolates, indicating
that this phenotype was indeed plasmid encoded.
Characterization of biofilm forming mutants. The nucleo-
tide sequences of the fimH genes from the 30 HDF biofilm-
forming clones were determined. The sequences revealed that
there were indeed only three different clone types; the three
plasmids were referred to as pMAS58, pMAS60, and pMAS64.
Plasmid pMAS58 was found in 24 of the 30 clones, plasmid
pMAS60 was found in 5 of the clones, and plasmid pMAS64
was present in 1 clone. All of the amino acid changes were
located within the first 155 amino acids of the mature FimH
protein (Fig. 3). Two of the FimH variants (pMAS58 and
pMAS60) contained multiple amino acid changes, while the
FimH of plasmid pMAS64 had only two amino acid changes.
The abilities of the clones to form a biofilm under HDF
conditions differed (Fig. 2). The FimH variant encoded on
pMAS58 conferred the highest level of biofilm formation, be-
ing about 2.5- and 6.5-fold better than pMAS60 and pMAS64,
respectively. This feature was reflected in the enrichment fre-
quency (80% of all isolated biofilm-forming clones).
Inhibition by soluble inhibitors. Under natural conditions
bacterial adhesion to eucaryotic cells is a function of the ability
of the adhesin to interact with the cognate receptor on the cell
surface but also depends on the sensitivity of the adhesin to
soluble inhibitory compounds that often bathe the cellular
target. Since the mutations in all three clones fall within the
D-mannose receptor recognition domain of FimH, we specu-
lated that the sensitivity to soluble inhibitors might be affected.
Therefore, we determined the sensitivity of the FimH variants
to biofilm formation under HDF conditions in the presence of
methyl-a-D-mannopyranoside. Interestingly, the biofilm-form-
ing abilities of strains harboring pMAS58 and pMAS60 were
only partially (35 and 10%, respectively) reduced under these
conditions (Fig. 2). In previously described experiments (28),
FimH-mediated biofilm formation under static growth con-
ditions was abolished by D-mannose. Thus, the pMAS58 and
pMAS60 FimH variants possess novel phenotypes that have
not been previously identified. In contrast to these results, the
weaker biofilm-forming FimH variant encoded by pMAS64
could not form a biofilm in the presence of methyl-a-D-man-
nopyranoside.
Detailed analysis of the amino acid changes in FimH. In an
attempt to define the amino acid changes in FimH responsible
for biofilm formation under HDF conditions, we used overlap-
ping PCR to split the mutations (Fig. 3). The fimH gene in the
predominant plasmid, pMAS58, contained nine amino acid-
altering mutations. The split derivative plasmids pPKL236 and
pPKL237 both turned out to be weaker HDF biofilm formers
than the parent. This suggests that the inherent biofilm forma-
tion phenotype of the pMAS58 FimH variant is the cumulative
result of several mutations within different regions of the re-
ceptor-binding domain. In contrast, the HDF biofilm-forming
phenotype of plasmids pMAS60 (six changes) and pMAS64
(two changes) could be at least partly attributed to a mutation,
G73E, found in both FimH variants. Apart from the presence
of this mutation in both clones, a significant biofilm-forming
potential was present in one of the split clones of pMAS60, i.e.,
pPKL239, harboring this mutation, whereas the other split
clone, pPKL238, exhibited no HDF biofilm formation (Fig. 2).
This led us to focus on the G73E change. Indeed, when the
G73E mutation was uniquely introduced into the wt fimH,
resulting in plasmid pTBK31 (Fig. 3), an HDF biofilm-forming
phenotype was observed (Fig. 2). Taken together, the data
demonstrate that a single amino acid substitution can enhance
the binding repertoire of the FimH adhesin and permit adhe-
FIG. 3. Depiction of mutations introduced into each of the FimH variants, along with a summary of their agglutination (Aggl.) and biofilm
phenotypes. a mm, methyl-a-D-mannopyranoside.
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sion to and biofilm formation on an abiotic surface under HDF
conditions.
Agglutination phenotypes of FimH variants. The classical
way to monitor type 1 fimbria-mediated adhesion to eucaryotic
cells is agglutination of erythrocytes or yeast cells. Yeast cell
agglutination is the most conserved binding property among
natural E. coli isolates and therefore was used to evaluate the
receptor binding exhibited by the biofilm-forming FimH vari-
ants. The pMAS58 FimH conferred a weak agglutination phe-
notype. Splitting of the mutations in this variant resulted in an
increased ability to agglutinate yeast cells in both progeny
clones (Fig. 3). In contrast, the pMAS60 FimH did not confer
an ability to agglutinate yeast cells. Furthermore, analysis of
the split clones revealed that some combination of the S114R,
N136Y, Q143L, and V155G mutations was responsible for abol-
ishing the mannose-binding ability of FimH. In this respect it is
important to note that mutagenesis of position 136 was previ-
ously shown to abolish agglutination (33). The pMAS64 FimH
also exhibited a reduced capacity to agglutinate yeast cells.
Biofilm formation induced by wt fimH alleles. We identified
the G73E mutation of the pMAS60 FimH variant as a func-
tional alteration involved in biofilm formation under HDF
conditions. Interestingly, the same mutation has also been
identified in the pathogenicity-adapted FimH variant of a wt
urinary tract isolate (38). The mutation in this variant imparts
a higher affinity for monomannose targets and thus provides an
adaptive advantage for the bacterial colonization of the urinary
tract (34, 36). We speculated that there might exist a correla-
tion between UTI FimH pathoadaptive phenotypes and HDF
biofilm formation potential. To test this, we examined a selec-
tion of clones expressing previously characterized wt fimH al-
leles from urinary tract isolates (37) for the ability to form
biofilms on abiotic surfaces. Indeed, all three of the strains
tested turned out to be very good HDF biofilm formers. Fur-
thermore, unlike our enriched clones, this biofilm formation
phenotype could be inhibited by mannose (Fig. 4). Two of
these strains (KB53 and KB96) also formed striking biofilms
on glass surfaces under HDF conditions (Fig. 5).
To explore this correlation further, we examined the biofilm
formation potential of FimH variants isolated from commensal
strains. To this end, we used the FimH alleles from E. coli K-12
strain PC31 and the wt strain F-18, both of which were origi-
nally isolated from normal human fecal flora (1, 6). The spe-
cific amino acid changes in these FimH alleles (15, 37) and
their adhesion to mannose substrates (35, 37) have been docu-
mented. Compared to the UTI FimH variants, the commensal
types displayed a significantly reduced ability to form HDF bio-
films on abiotic surfaces (Fig. 4). This is the first report to doc-
ument a correlation between HDF biofilm formation on abi-
otic surfaces and UTI pathogenicity-adapted FimH phenotypes.
DISCUSSION
In natural aquatic environments surfaces are often exposed
to HDF conditions. The urinary tract is such an example, and
bacteria infecting the urinary tract are faced with brutal HDF
shear forces. An obvious way for bacteria to counter this prob-
lem is to express efficient adhesions, enabling them to attach
and eventually form sessile communities or biofilms. More
than 50% of all microbial infections have now been associated
with the formation of biofilms (9). In the urinary tract, biofilm
formation is associated with chronic cystitis and infections re-
lated to medical implants such as catheters (24). The majority
(80%) of urinary tract infections in humans are caused by
E. coli. UTIs are a huge burden on our health care system; it
is estimated that between 50 and 80% of women will experi-
ence at least one UTI infection at some time (11).
Uropathogenic E. coli express a number of different adhe-
sive organelles including type 1, P, S, and F1C fimbriae. It is
now well established that type 1 fimbriae are required for E.
coli virulence of the urinary tract and that the FimH adhesin is
instrumental in this regard (7, 25, 36). More recent data indi-
cate that FimH can directly trigger host cell signaling cascades
that lead to bacterial internalization (23). Type 1 fimbriae have
also been described as key factors in biofilm establishment on
abiotic surfaces (29). More specifically, the FimH adhesin was
shown to be required for adherence to abiotic surfaces under
static growth conditions. In this study, we used a novel random
mutagenesis approach followed by a selection-enrichment pro-
cedure to specifically identify FimH variants capable of medi-
ating biofilm formation on abiotic surfaces. Furthermore, to
more realistically mimic real-life scenarios, our selection pro-
cedure was performed under HDF conditions.
We have previously demonstrated that the PCR mutagenesis
approach used to construct our FimH mutant library was
highly successful for the introduction of a limited number of
FIG. 4. Biofilm formation under HDF conditions on a microtiter
plate surface by recombinant E. coli cells expressing fimH alleles from
UTI isolates (KB28, KB53, and KB96) and commensal isolates (KB91
and MS72). Results are expressed as the average of four independent ex-
periments (6 standard deviation). a mm, methyl-a-D-mannopyranoside.
FIG. 5. Biofilm formation on a glass surface by recombinant E. coli
cells expressing fimH alleles from UTI isolates (KB28, KB53, and
KB96) and commensal isolates (MS72 and KB91). Cultures were
grown overnight in LB under HDF conditions.
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random structural alterations in the FimH primary sequence.
Nucleotide sequences were distributed randomly along the tar-
get sector, and the observed amino acid changes were diverse
in nature (34). Therefore, it is intriguing that although the
targeted region encompassed codons 8 to 225, no changes
resulting in amino acid alterations were identified in the fimH
alleles of the three clones enriched for HDF biofilm formation
downstream of codon 155. For the sake of completeness, it
should be noted that the fimH allele of plasmid pMAS60 con-
tained two nucleotide changes downstream of codon 155 that
did not alter the amino acid sequence. Thus, it appears that
FimH-mediated biofilm formation as defined by our selection
procedure is specifically linked to alterations in the N-terminal
receptor-binding domain of the protein.
We identified three FimH variants that could mediate bio-
film formation on abiotic surfaces subjected to HDF condi-
tions. Two of these HDF biofilm library clones (pMAS58 and
pMAS60) were partly immune to mannose inhibition. The strong-
est biofilm former identified in our selections was that encod-
ed by the most predominantly enriched plasmid, pMAS58.
From our split clones it is clear that some combination of the
W103R, S113G, and V118A alterations is critical to impart this
phenotype. In the case of plasmid pMAS60, biofilm formation
was also associated with multiple amino acid changes. Our data
indicates that the G73E mutation is required in combination
with other changes to produce this phenotype. This mutation
was also present in an independently isolated clone (pMAS64),
providing additional evidence that it has a functional impact on
the HDF biofilm formation phenotype. Furthermore, when the
G73E change was introduced separately into the parental K-12
FimH background (i.e., plasmid pTBK31), enhanced biofilm
formation was observed. When we compared the mutations in
our enriched clones with those already documented in UTI
FimH variants, some striking similarities were noted. First, the
G73E mutation has been identified as the functional change
in a naturally occurring FimH variant (38). In the case of the
FimH encoded by the predominant plasmid pMAS58, the
functional changes associated with biofilm formation partially
overlap with a deletion of four amino acids (117 to 120) iden-
tified in another naturally occurring UTI FimH variant (38).
These similarities between our own in vitro-selected clones and
naturally occurring pathogenicity-adapted isolates prompted
us to investigate biofilm formation mediated by naturally oc-
curring FimH variants.
We examined three UTI FimH variants for their role in
biofilm formation on abiotic surfaces subjected to HDF con-
ditions. These variants have been well characterized with re-
gard to their mannose-binding properties, and all contain mi-
nor amino acid changes in their amino-terminal domains that
result in altered receptor specificity (35, 38). Furthermore, all
three recombinant strains carrying the wt fimH alleles are
similar with regard to level of fimbriation and relative levels
of FimH incorporation, and importantly they are identical to
the respective parental clinical isolates with regard to FimH
adhesive phenotypes (37). We observed that these structural
changes also impart an ability to form HDF biofilms on abiotic
surfaces. It is intriguing to speculate on this correlation and the
implications for pathogenesis. The ability to form biofilms is
clearly a well-defined virulence trait among bacteria infecting
the urinary tract (9). Thus, in addition to adhesion to mannose-
containing substrates, FimH may be critical for the formation
of biofilms in a hydrodynamic environment such as the urinary
tract. Furthermore, the data implicate FimH as a potential
mediator of biofilm formation on abiotic medical devices such
as catheters.
FimH variants from E. coli strains of human fecal origin
differ in receptor specificity from those from UTI isolates.
Indeed, FimH variants from commensal isolates primarily rec-
ognize oligomannose-like receptors, while those from UTI iso-
lates preferentially bind monomannose-like receptors and pro-
vide an adaptive advantage for bacterial colonization of the
urinary tract (36). We examined HDF biofilm formation me-
diated by FimH variants from two commensal strains isolated
from human fecal flora (E. coli K-12 strain PC31 and the wt
strain F-18). Contrary to the FimH variants of UTI origin, the
FimH variants from both of the commensal strains did not
promote significant biofilm formation on abiotic surfaces un-
der HDF conditions. Taken together, these findings suggest
that the UTI FimH variants may have a greater capacity for
HDF biofilm formation. At this stage one can only speculate
on the role such FimH variants might play in establishing bio-
films in the urinary tract, especially in catheterized patients.
Although there might not be a complete correlation between
HDF biofilm-forming FimH variants and pathogenicity, it may
be that the biofilm assay described here could be used as a
crude, yet simple and inexpensive means for differentiation of
clinical isolates to indicate potential UTI pathogens.
Complicated UTIs and bacterial biofilms on the surface of
catheters are often refractory to treatment with antibiotics.
Our current knowledge suggests a multifunctional role for
FimH in virulence traits that encompass adhesion, biofilm for-
mation, and invasion. Our proposed role for FimH in biofilm
formation on surfaces subjected to HDF conditions may lead
to a better understanding in the design of treatment regimens
to prevent UTIs. We have shown that the pathogenicity-adap-
tive phenotype that specifies altered affinity for different FimH
alleles toward monomannose and trimannose can now be ex-
tended to include adherence to abiotic surfaces under HDF
conditions. This novel phenotype has not previously been
observed in naturally occurring FimH variants. Natural UTI
FimH variants are probably functional compromises selected
for their abilities to target and bind to mannose receptors and
to form HDF biofilm. It is possible that the specific FimH
isotypes enriched in our assays represent adhesive phenotypes
selected against in the urinary tract. A highly intriguing aspect
of this work is the observation that UTI FimH alleles possess
greater biofilm formation potential than their commensal FimH
counterparts.
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